SecBot SecBot
8-K ·Filed Apr 30, 2026

AWHL

Aspira Women's Health Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0000926617-26-000029
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The fractional CFO role and low cash compensation signal ongoing cash conservation. Monitor for proxy fight outcomes and Q2 2026 financials to assess if cost cuts are sufficient.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
AWHL ▼ -10.03% at T+60d
NEUTRAL call -10.03% · α vs SPY -13.09% · entry $0.3900 → $0.3509
Entry = T+0 close
Apr 30, 2026
via day close
T+1d
-7.69%
call -7.69% · α -7.35%
$0.3600
settled 6mo ago
T+5d
+10.26%
call +10.26% · α +7.91%
$0.4300
settled 6mo ago
T+20d
+38.46%
call +38.46% · α +33.20%
$0.5400
settled 5mo ago
T+60d
-10.03%
call -10.03% · α -13.09%
$0.3509
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Aspira Women's Health appointed John Strahley as CFO/CAO effective April 27, 2026, replacing Brian Hungerford who departed for personal reasons. The new CFO will work part-time (20 hrs/week) with a $167K salary and option grant, reflecting cost-consciousness amid a proxy contest context.

Key Facts

  • John Strahley appointed CFO/CAO effective April 27, 2026
  • Prior CFO Brian Hungerford left voluntarily (personal reasons)
  • Strahley works fractional capacity: minimum 20 hours/week
  • Annual base salary of $167,000, no health/dental/vision benefits
  • Options to purchase 70,000 shares: 25% vest after 90 days, remainder over 9 months
  • DEFA14A filed 2 days prior indicates active proxy contest

Financial Impact

New CFO compensation disclosed: $167,000 annual salary plus 70,000 options; no material change to financials.

executive compensationshare-based compensation

Risk Factors

  • Part-time CFO may strain financial oversight during proxy contest
  • Potential further management turnover given governance instability
  • No severance could make retention of new CFO less certain

Market Snapshot

Exchange
OTC
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000926617-26-000029
Document: 0000926617-26-000029-index-headers.html0000926617-26-000029
Document: 0000926617-26-000029-index.html0000926617-26-000029
Document: 0000926617-26-000029.txt0000926617-26-000029
6 reports for AWHL
Performance horizon
67% Hit rate @ T+60 2 of 3 directional calls Went positive at some point 2 of 3 best @ T+60▲ +36.96%Jun 22, 2026
Filters
Rows
Reports for AWHL — sortable, filterable
TypeNow
Jun 22, 2026
18w ago
8-K
BEARISH ★ 5/10
$0.4600 $0.2900▲ +36.96%▲ +39.17%$0.1388 (+69.83%)
Jun 9, 2026
20w ago
8-K
BEARISH ★ 6/10
$0.4300 $0.2786▲ +35.21%▲ +39.29%$0.1388 (+67.72%)
May 29, 2026
21w ago
Insider Cluster
BULLISH ★ 5/10
$0.5400 $0.2700▼ −50.00%▼ −51.23%$0.1388 (−74.30%)
May 26, 2026
22w ago
8-K
NEUTRAL ★ 4/10
$0.4600 $0.3100▼ −32.61%▼ −35.33%$0.1388 (−69.83%)
Apr 30, 2026
25w ago
8-K
NEUTRAL ★ 3/10
$0.3900 $0.3509▼ −10.03%▼ −13.09%$0.1388 (−64.41%)
Apr 28, 2026
26w ago
DEFA14A
NEUTRAL ★ 3/10
$0.4000 $0.4000· 0.00%▼ −4.11%$0.1388 (−65.30%)
Showing 6 of 6

US Market Status

Market Closed — Opens Thu (11h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026